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Background: The aryl hydrocarbon receptor (AhR) ligand 6-Formylindolo(3,2-b)carbazole (FICZ) has received
increasing attention since its identification as an endogenous AhR ligand and a photoproduct of tryptophan.
FICZ and its metabolites have been detected in human fluids. We recently reported that AhR promotes retinoic
acid (RA)-induced granulocytic differentiation of HL-60 myeloblastic leukemia cells by restricting the nuclear
abundance of the stem cell associated transcription factor Oct4. The standard clinical management of acute
promyelocytic leukemia (APL) is differentiation induction therapy using RA. But RA is not effective for other myeloid
leukemias, making the mechanism of RA-induced differentiation observed in a non-APL myeloid leukemia of
interest. To our knowledge, this is the first study regarding the influence of FICZ on RA-induced differentiation in
any type of leukemic blasts.
Methods: Using flow cytometry and Western blotting assays, we determined the effects of FICZ on RA-induced
differentiation of HL-60 human leukemia cells. All experiments were performed in triplicate. The groups RA and
FICZ + RA were compared using the Paired-Samples T-Test. Western blot figures present the typical blots.
Results: We demonstrate that FICZ enhances RA-induced differentiation, assessed by the expression of the membrane
differentiation marker CD11b; cell cycle arrest; and the functional differentiation marker, inducible-oxidative
metabolism. FICZ causes changes in signaling events that are known to drive differentiation, and notably augments
the RA-induced sustained activation of the RAF/MEK/ERK axis of the mitogen-activated protein kinase (MAPK) cascade.
FICZ also augments expression of the known MAPK signaling regulatory molecules c-Cbl, VAV1, pY458 p85 PI3K,
Src-family kinases (SFKs), and IRF-1, a transcription factor associated with this putative signalsome that promotes
RA-induced differentiation. Moreover, FICZ in combination with RA also increases expression of AhR and even more so
of both Cyp1A2 and p47phox, which are known to be transcriptionally regulated by AhR. pY1021 PDGFRβ, a marker
associated with retinoic acid syndrome was also increased.
Conclusions: Our data suggest that FICZ modulates intracellular signaling pathways and enhances RA-induced
differentiation.
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Retinoic acid (RA) induces leukemic cell differentiation in
a process that depends on AhR [1]. AhR overexpression
drives differentiation [1]. This motivates interest in the ef-
fects of an endogenous AhR ligand on this process. AhR is
a ligand activated receptor. There are two intensely stud-
ied AhR functions, both being ligand dependent. AhR is a
basic helix-loop-helix/Per-Arnt-Sim (bHLH-PAS) tran-
scription factor [2], and also an adaptor in the cullin 4B
ubiquitin ligase complex [3]. It has been found to be
expressed in all tissues analyzed. It is present in the cyto-
sol and in the nucleus. Its transcriptional activity is the
most studied, especially its regulation of detoxification en-
zymes such as cytochrome P450 [4]. The RAR/RXR and
AhR pathways are known to crosstalk. For example, they
compete for the silencing mediator of retinoid and thyroid
receptors (SMRT) protein [5]. Consistent with various
molecular indications of crosstalk, the two pathways can
give rise to similar pathologies. For example, teratogenic
effects such as cleft palate and hydronephrosis can be in-
duced by retinoids [6] and also by an AhR agonist, 2,3,7,
8-tetrachlorodibenzo-p-dioxin (TCDD) [7]. They can also
contribute to common developmental processes. For ex-
ample, in fish, RA and its receptors are required both for
AhR transcription and embryonic development of blood
vessels and bones [8]. AhR can thus regulate RA effects,
as well as vice versa, but the mechanisms are not well
understood.
Recently, several papers reported that the AhR gene
can act as a tumor suppressor in the absence of xenobi-
otics. AhR has been shown to have a role in propelling
breast cancer [9] and liver cancer [10] cell differenti-
ation. AhR knockout mice injected with the liver tumor
initiator diethylnitrosamine (DEN) have increased liver
tumor formation and growth, with increased cell prolif-
eration, inflammatory cytokine expression and DNA
damage compared to wild type mice treated with DEN
or untreated mice [10]. Moreover, the AhR knockout
mice have increased cecal carcinogenesis [11]. Certain
AhR antagonists promote hematopoietic stem cell pro-
liferation [12]. The full molecular mechanism of AhR-
dependent tumor suppressing activity is far from being
elucidated; however, some details are emerging. Histor-
ically, the most studied function of AhR is its transcrip-
tional activity elicited by xenobiotics. Recently it has
become apparent that xenobiotics and endogenous li-
gands have different transcriptional properties, leading
to opposite outcomes. For example, it was proposed
that transient AhR transcriptional activity, characteris-
tic of endogenous ligands such as 6-Formylindolo(3,
2-b)carbazole (FICZ), is essential for the role of AhR in
stem/progenitor cell homeostasis, whereas prolonged
transcriptional activation is induced by exogenous li-
gands, such as TCDD, a well known carcinogen [13].The more recently emerging role of AhR in protein deg-
radation via CUL4B/AhR-mediated ubiquitylation and
consequently cancer suppression is also of potentially
related significance [11]. While the mechanisms are not
yet clear, it appears that depending on the model system
and on the ligand used, AhR can drive transformation
or differentiation.
We have previously shown that AhR propels RA-
induced differentiation of human myeloblastic leukemia
cells by downregulating the nuclear transcription factor,
Oct4 [1]. Oct4 is a Yamanaka-Thomson factor control-
ling stem cells [14-16]. This process depends on MAPK
signaling. This motivates interest in the effect of en-
dogenous AhR ligands, such as FICZ, on the MAPK
pathway and its associated signaling events known to
drive RA-induced differentiation. Unlike transcription,
the effects of FICZ on signaling are less explored and re-
main to be better described.
One well studied model of leukemic cell differentiation
is HL-60. HL-60 is a human myeloblastic leukemia cell line
that is lineage uncommitted and capable of granulocytic or
monocytic differentiation in response to different agents.
HL-60 is a NCI-60 line, a set of standard cell lines, used
for example in drug testing. It has been extensively used as
a model for pharmacologically induced differentiation. HL-
60 cells undergo granulocytic differentiation with G0/G1
growth arrest when treated with RA. This process requires
sustained activation of MAPK signaling along the RAF/
MEK/ERK axis [17], and a cascade of signaling regulatory
events involving Src-family kinases, c-Cbl, VAV1, PI3K,
and IRF-1 [18-22]. During RA-induced differentiation, ec-
topic expression of interferon regulatory factor 1 (IRF-1)
[21] and c-Cbl [19] have been shown to enhance ERK 1/2
activation and promote RA-induced differentiation and
G0/G1-arrest. The VAV1 guanine nucleotide exchange fac-
tor implicated in myelopoiesis also was reported to pro-
mote RA-induced granulocytic differentiation [23].
The present study demonstrates that FICZ is able to
augment RA-induced differentiation. FICZ increases the
amount and activation of key components of the MAPK
signaling cascade known to drive differentiation, and this
signaling modulation is consistent with a ligand bound
AhR dependence as demonstrated by using the classical
pharmacological AhR agonist β-naphthoflavone (β-NF)
and antagonist α-naphthoflavone (α-NF). These had posi-
tive and negative effects on the signaling events consistent
with their AhR agonist vs. antagonist activity. The findings
suggest a novel potential mechanism of collaboration
between RA and FICZ during RA-induced differentiation
of t(15;17) negative leukemic blasts.
Results and discussion
The capability to prevent and treat leukemia depends upon
understanding the molecular underlying mechanisms of
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tosis and (c) resistance to therapy. Multiple pathways are
involved in each of these three aspects; however the aryl
hydrocarbon receptor (AhR) is strikingly involved in all
three of the above mentioned phenomena. We have shown
that during RA-induced differentiation, AhR propels dif-
ferentiation [1]. We now sought evidence on whether
FICZ, an endogenous AhR ligand in humans, affects RA-
induced leukemic cell differentiation.
FICZ augments RA-induced differentiation markers
To determine if FICZ influenced RA-induced differenti-
ation, HL-60 cells were treated with both agents eitherFigure 1 FICZ augments RA-induced differentiation. HL-60 cells were u
indicated times. FICZ augments RA-induced expression of differentiation m
APC-conjugated antibody) at 6 h post treatment is not significantly modula
expression (assessed by flow cytometry with APC-conjugated antibody) wa
24 h (p = 0.012), C. 48 h (p = 0.042) and D. 72 h (p = 0.0029) of treatment. F
gate to exclude 95% of the untreated cells during CD38 and CD11b detect
were measured using flow cytometry of DCF stained cells. Respiratory burs
compared to RA alone (p = 0.08). F. Respiratory burst, measured by flow cy
co-treatment compared to RA alone (p = 0.001). G. Cell density was measu
h. Cell growth shows that FICZ at the concentration used has no toxic effe
enhances RA-induced growth inhibition. H. Cell cycle distribution was mea
percent of cells in G0/G1 is shown. G0/G1 cell-cycle arrest was propelled b
I. 72 h(p = 0.035) as shown by flow cytometry of DNA-stained nuclei.alone or in combination, and consequential occurrence of
differentiation markers was measured. RA-induced gra-
nulocytic differentiation is characterized by the appearance
of several phenotypic differentiation markers. These in-
clude: cell surface CD11b, cell cycle arrest in G0/G1, and
inducible respiratory burst - a classical functional differen-
tiation marker that is a characteristic response of mature
myeloid cells to bacterial cell components. FICZ (100 nM)
by itself had no effect on these markers. Co-administered
with RA, FICZ enhanced the induced expression of these
markers compared to RA alone.
Cells were untreated or treated with 1 μM RA with or
without 100 nM FICZ. Expression of the CD38 and CD11bntreated (C, control) or treated with FICZ, RA, or RA plus FICZ for
arkers. A. CD38 expression (assessed by flow cytometry with
ted either by FICZ alone or in combination with RA. B. CD11b
s increased by the combination therapy compared to RA alone after
low cytometric assay of live cells was carried out setting the logical
ion. E. Superoxide metabolites from inducible oxidative metabolism
t is not significantly enhanced at 48 h by combination therapy
tometry of DCF stained cells, is significantly enhanced at 72 h by
red for control and treated cells at progressive times, 0, 24, 48 and 72
ct. FICZ by itself does not decrease the cell number, however it
sured by flow cytometry of propidium iodide stained nuclei. The
y co-treatment compared with RA alone both at 48 h (p = 0.009) and
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(measured as inducible reactive oxygen species) and the
percentage of cells with G0/G1 DNA were measured
by flow cytometry (Figure 1). CD38 is an early cell sur-
face differentiation marker. At 6 h, FICZ alone did not
induce CD38 expression. Likewise, FICZ did not affect
RA-induced CD38 expression at this early time (Figure 1A).
CD11b is the alpha subunit of the integrin receptor and is
a differentiation marker that typically appears with slower
kinetics than CD38 in RA-treated cells. For CD11b expres-
sion, the percentage of cells that were positive was higher
for cells treated with RA plus FICZ compared to RA alone,
namely 26% versus 21%, p = 0.012 after 24 h (Figure 1B),
62% versus 50%, p = 0.042, after 48 h (Figure 1C) and 84%
versus 57%, p = 0.0029, after 72 h (Figure 1D). The flow
cytometry raw data and mean fluorescence index for a
representative experiment (48 h and 72 h) are presented in
Additional file 1: Figure S1. Cells treated with FICZ alone
showed no CD11b expression – like untreated controls.
Inducible oxidative metabolism is a functional marker
of further differentiation that is characteristic of mature
cells. This mature functional differentiation marker was
also enhanced in cells treated with FICZ plus RA com-
pared to RA alone. At 48 h, FICZ plus RA treated cells
were 57% positive compared to 39% for cells treated
with RA alone with a p = 0.08 (Figure 1E), and by 72 h
84% of FICZ plus RA treated cells were positive versus
63% of RA treated cells with a p = 0.001 (Figure 1F).
G0/G1 cell cycle arrest is a characteristic of differenti-
ation. RA caused an increase in the relative number of
G0/G1 cells and an associated reduction in S phase cells.
Addition of FICZ with RA enhanced this effect (Figure 1H
and 1I), consistent with the enhanced phenotypic shift. At
48h (Figure 1H), 48% cells were in G0/G1 phase for un-
treated cells, and 56% for RA treated cells, p < 0.0001. At
72 h (Figure 1I), the proportions were 56% and 72% for
untreated and RA treated respectively (p < 0.001). FICZ
alone had a slightly lower proportion of cells in G0/G1
compared to untreated cells (46% vs. 48%, p = 0.2 at 48 h,
and 54% vs. 56%, p = 0.01 at 72 h). For cells treated with
FICZ plus RA compared to RA alone, the percentage of
cells with G0/G1 DNA was 66% compared to 56%, p <
0.0001, after 48 h; and 85% versus 72%, p < 0.0001, after
72 h. Growth curves (Figure 1G) were consistent with the
cell cycle phase distribution changes. FICZ alone did not
significantly affect, although slightly increased, the cell
density compared with control (1.5 ± 0.08 × 106 cells/ml
for control, and 1.6 ± 0.1 × 106 cells/ml for FICZ at 72h
post-treatment). FICZ in combination with RA lowered
the cell densities compared to RA alone (0.96 ±0.15 × 106
cells/ml for the combination treatment and 1.3 ± 0.1 × 106
cells/ml for RA alone at 72 h post-treatment) consistent
with the G0/G1 data. FICZ thus enhances RA-induced
CD11b expression, inducible oxidative metabolism, andG0/G1 arrest, but does not modulate these parameters by
itself in the absence of RA. FICZ caused no evident to-
xicity, evaluated by trypan blue exclusion or population
growth, and FICZ-treated cells had similar cell cycle phase
distribution and growth curves as untreated control cells.
Given the positive effects of FICZ on RA-induced diffe-
rentiation, we sought evidence that the FICZ as presented
in this context could regulate the transcriptional activity
of AhR by determining its effects on two classical AhR
transcriptionally regulated targets: Cyp1A2 and p47phox.FICZ augments the expression of classical AhR
transcriptionally regulated genes
The expression of cytochrome P450 1A2 (Cyp1A2), neu-
trophil cytosolic factor-1 (p47phox), and aryl hydrocarbon
receptor (AhR), were analysed after 48 h of treatment with
FICZ, RA or their combination using Western blotting
(Figure 2). We found that relative levels of Cyp1A2 and
p47phox proteins were clearly increased by the combi-
nation therapy (lane 4) compared with untreated control
cells (lane 1). Addition of FICZ to RA (lane 4) also in-
creased Cyp1A2 and p47phox expression compared to
RA only-treated cells (lane 2). Cyp1A2, an endogenous
reporter of classical AhR driven transcriptional activa-
tion thus behaved as expected. RA alone did not induce
Cyp1A2 expression, and FICZ induced it both alone and
more strongly with RA. The protein p47phox, a NADPH
oxidase subunit of the complex producing the respirato-
ry burst, was also reported to be under AhR transcrip-
tional control [24]. In contrast to Cyp1A2, the changes in
p47phox expression depended on the presence of RA.
FICZ was able to upregulate p47phox expression only in
RA-treated cells. This was anticipated since p47phox
expression is a characteristic of mature myeloid cells, and
RA is needed to cause granulocytic differentiation. AhR ex-
pression was modestly increased by RA plus FICZ (lane 4)
compared to RA alone (lane2). Previous reports showed
that AhR protein expression is augmented by treatment
with RA [1] or FICZ alone [25] and we confirmed this
(lane 2 vs lane 1 or lane 3 vs lane 1). FICZ thus increases
the expression of genes that are classical targets of AhR.
While the present results are consistent with action
through AhR, there could be a variety of other transcrip-
tion factors that also contribute to the FICZ induced
effects observed.
It is now well established that a transient activation of
the MAPK signaling cascade elicits cell proliferation,
whereas prolonged activation leads to differentiation
[17,26]. In particular RAF activation is known to drive
RA-induced differentiation [27]. We therefore assessed
the effects of FICZ on the MAPK cascade, specifically
the RAF/MEK/ERK axis that is activated during RA-
induced differentiation.
Figure 2 FICZ upregulates: AhR, AhR target genes and MAPK
cascade components in the presence of RA. Cell lysates
collected 48 h after initiation of the experiments were resolved on
12% polyacrylamide gels. 25 μg protein was loaded per well. In
RA-treated cells, FICZ upregulates the amount of Cyp1A2, and
p47phox, AhR protein expression and pERK1/2, pMEK1/2 and
pS621 RAF phospho-protein in the presence of RA compared to
cells treated with RA alone. Like pS621 RAF, terminal domain
phosphorylated RAF is also upregulated. Total ERK1/2, MEK1/2, RAF
are unchanged. The loading control was GAPDH.
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MAPK signaling during RA-induced differentiation uti-
lizes c-RAF activation, specifically pS621 c-RAF phosphor-
ylation, which is necessary to induce terminal granulocytic
differentiation [27]. Western blot analysis confirms that
FICZ and RA co-treatment enhances c-RAF activation
(Figure 2) compared to RA alone. FICZ alone had no ef-
fect. The same behavior is true for the other two compo-
nents of the MAPK cascade: pMEK1/2 and pERK1/2.
Total amounts of c-RAF, MEK, and ERK in contrast were
not upregulated in this time frame (48 h) by FICZ or FICZ
plus RA. The data thus indicate FICZ regulates intracellu-
lar signaling events, but not c-RAF, MEK or ERK abun-
dance – such as might occur through AhR regulated
transcription or protein stability. Interestingly, FICZ and
RA co-treatment also resulted in increased phospho-c-
RAF pS289/296/301 (TD RAF) compared to RA alone.
This C-terminal domain of c-RAF is phosphorylated du-
ring RA-induced differentiation and is thought to be part
of a putative feedback loop characterizing hyperactiveMAPK signaling needed for differentiation [18]. In other
contexts, it is also known to be phosphorylated by ERK1/2
[28] and can make the c-RAF molecule unresponsive to fur-
ther stimulation [29], suggesting that this phosphorylation
event may have a diversity of potential effects dependent on
context. FICZ thus augments the RA-induced activation of
the RAF/MEK/ERK axis. The enhanced activation is con-
sistent with the occurrence of enhanced differentiation at-
tributed to FICZ above.
The MAPK signalsome that drives RA-induced dif-
ferentiation is known to contain a number of regulatory
molecules that propel differentiation. We thus sought
evidence of their involvement consequential to FICZ.
Interestingly, the signalsome has been found to contain
the transcription factor IRF-1 which has also been found
to propel RA-induced differentiation [21].
MAPK signaling cascade modulation by FICZ is consistent
with modulation of other signalsome regulatory
molecules of the RA-induced differentiation process
c-Cbl and IRF-1 have been previously shown to be in-
strumental in RA-induced differentiation; specifically, in-
creased expression propelled differentiation [21]. Cells were
treated with RA or FICZ alone or in combination, and ex-
pression of c-Cbl, pY507 Lyn, RARα, IRF-1 and pY1021
PDGFRβ was measured. FICZ augments the RA-induced
increases in c-Cbl and IRF-1 (Figure 3). This is consistent
with previous results where we have shown that AhR ex-
pression induced IRF-1, and IRF-1 physically interacted
with c-Cbl [21]. To confirm that the increases in amount
of protein that we observe are not attributable to a general
nonspecific increase in protein synthesis, we have con-
firmed that the amount of RARα or GAPDH did not in-
crease. Lyn is a member of the Src-family kinases (SFKs),
and its binding to c-RAF in RA treated cells is enhanced
by the SFK inhibitor PP2, which enhanced RA-induced
differentiation [18]. We reported that a scaffolding func-
tion of Lyn – not its kinase activity – was important for
RA-induced differentiation [18]. Phosphorylation of Lyn
at Y507 increases autoinhibition of its kinase activity [30].
RA increases the amount of pY507 Lyn and addition of
FICZ augments this, again consistent with a role of FICZ
in enhancing RA-induced effects on signaling molecules.
We also assessed pY1021 PDGFRβ expression. pY1021
PDGFRβ is potentially significant as a marker of neu-
trophil hyperactivation, consistent with the report that
pY1021 PDGFRβ is a marker of retinoic acid syndrome
[31]. It was also up regulated by RA, and addition of FICZ
to the RA further enhanced it. FICZ thus enhanced RA ef-
fects on a number of RA-targeted signaling regulatory
molecules associated with induced differentiation.
We sought evidence to corroborate the putative action
of FICZ through AhR to drive signaling effects by using
other known AhR agonists and antagonists.
Figure 3 FICZ upregulates RA-dependent signaling
intermediates. Cell lysates collected at 48 h time point were
resolved on 12% polyacrylamide gels. 25 μg protein was loaded per
well. FICZ upregulates the amount of c-Cbl and IRF-1 expression and
pY507 Lyn and pY1021 PDGFRβ phospho-protein. Total RARα
expressed is not upregulated, nor is the GAPDH loading control.
Figure 4 AhR ligands modulate phosphorylation of RAF in the
MAPK signaling cascade. Cell lysates collected 48 h after initiation
of the experiments were resolved on 12% polyacrylamide gels.
25 μg protein was loaded per well. β-NF upregulates the amount of
Cyp1A2, TD RAF and pS621RAF proteins in the presence of RA in a
similar fashion to FICZ (comparing similarity of lanes 4 and 8),
whereas α-NF does not. GAPDH is the loading control.
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The ability of FICZ to modulate signaling molecules in
the context of RA-treated cells is novel. FICZ is an en-
dogenous AhR ligand. This motivated interest in deter-
mining if other AhR ligands also had consistent effects on
signaling. Two well characterized exogenous AhR ligands
were used: an AhR antagonist, α-NF, and an agonist, β-NF,
at a concentration of 1 μM each. Cells were treated with
RA, FICZ, α-NF or β-NF as shown in the figures. The ef-
fects on Cyp1A2, TD RAF and pS621 c-RAF were mea-
sured by Western blotting as shown in Figure 4. Cyp1A2
is a classical responder to AhR activation and was used to
confirm the ability of the ligands to activate AhR or not.
FICZ increases Cyp1A2 expression and behaves as an
AhR agonist as expected. At the concentration used β-NF
elicits Cyp1A2 expression also, whereas α-NF does not,
consistent with their known roles as an AhR agonist or
antagonist, respectively. RA augments the effects of the
AhR agonists (FICZ or β-NF), but not the antagonist. This
suggests cooperativity between RA and the agonists (with
lanes 4 and 8 of Figure 4 having the strongest signals).
We next determined if there were corresponding coopera-
tive effects on signaling events believed to drive RA-
induced differentiation. RA-induced upregulation of the
C-terminal domain phosphorylated RAF (TD-RAF), and
this is enhanced by the AhR agonists (FICZ and β-NF),
but not by the antagonist (α-NF). There are similar but
more subtle effects on the expression of pS621 c-RAF. RA
and the agonists again cooperate, and pS621 c-RAF ex-
pression is greater for RA plus agonist than RA alone.
Both the C-terminal domain and S621 c-RAF phosphory-
lations are characteristic of RA-induced signaling. Hence
the TD RAF and pS621 c-RAF responses to RA are aug-
mented by AhR agonists.The RA-regulated RAF/MEK/ERK axis has been found
to be associated with a number of signaling regulatory mo-
lecules in a putative signalsome that propels RA-induced
differentiation. Prominent MAPK signaling regulators in
the RA-induced signaling cascade leading to RA-induced
differentiation that have emerged are: Src-family kinases
[18], VAV1 [23,32] and PI3K [22]. Cells were treated with
RA or the antagonist or agonists singly or in combination
with RA as above and the expression of these targeted sig-
naling molecules was measured. The protein levels and ac-
tivation of these signaling molecules are modulated during
RA-induced differentiation by AhR ligands (Figure 5). Fgr,
a SFK, is one of the most responsive of these proteins.
RA-induced upregulation of Fgr is enhanced by FICZ and
β-NF, AhR agonists, but is crippled by α-NF, an AhR antag-
onist. The AhR ligands by themselves had no discernible
effect on expression, indicating an AhR role dependent on
the RA-induced context. Consistent with this, the enzy-
matically active form of SFKs discerned by probing with
a p-Y416 pan-Src-family kinase antibody also responded
similarly to the AhR ligands as seen for Fgr expression.
The results are consistent with earlier observations for
these cells that the SFKs are progressively activated by
tyrosine phosphorylation after RA treatment and reach
maximum phosphorylation 48 hours post treatment [33].
Taken together, these observations are thus consistent with
a role for these kinases in driving differentiation. Interes-
tingly, the pY507 Lyn is also regulated likewise by RA and
the AhR agonists and antagonist (lanes 4 and 8 Figure 5
show the strongest signal again). This phosphorylation site
has been implicated with a negative role in another context
[34]. This is consistent with a previous suggestion that Lyn
performs a scaffold function important for the signalsome
to drive differentiation [18]. The total amount of Lyn, the
VAV1 guanine nucleotide exchange factor and pY458 p85
PI3K also exhibit a similar enhancement after RA plus
Figure 5 FICZ and other AhR ligands modulate MAPK signaling
cascade regulatory molecules. Cell lysates collected after 48 h of
RA treatment were resolved on 12% polyacrylamide gels. 25 μg
protein was loaded per well. Similarly to FICZ, β-NF upregulates the
amount of Fgr, Lyn, VAV1 protein and p-Y416 pan-SFK, pY507 Lyn,
and pY458 p85PI3K phospho-protein, whereas the antagonist does
not upregulate those markers Comparing lanes 4 and 8 FICZ and
β-NF, the two AhR agonists, have apparently similar signaling
profiles in RA-treated cells, which is not shared by α-NF, an AhR
antagonist, lane 6). The agonists by themselves without RA do not
have this effect. GAPDH is the loading control.
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ever the effects of α-NF and β-NF on total Lyn, VAV1, and
pY458 p85 PI3K are minor compared to the modulation
of Fgr, p-Y416 pan-SFK and pY507 Lyn. In sum, our re-
sults show that the effects of the β-NF agonist and α-NF
antagonist on certain signaling molecules that are impli-
cated as part of the RA-regulated MAPK signaling com-
plex are consistent with a role for AhR in driving FICZ
augmentation of RA-induced differentiation via effects on
components of the putative signalsome. However, some
components are more responsive than others.
Conclusions
Taken together our results show that FICZ enhances RA-
induced differentiation as evidenced by CD11b membrane
receptor expression, inducible respiratory burst, G0/G1
cell cycle arrest and growth curves. Upregulation of sig-
naling molecules previously shown to drive RA-induced
differentiation was enhanced by addition of FICZ. Specif-
ically, FICZ augments RAF/MEK/ERK axis MAPK signa-
ling, Src-family kinase activation and the RA-dependent
upregulation of VAV1, c-Cbl, pY458 p85PI3K, and IRF-1
expression. Interestingly, in the case of PDGFR which dif-
ferentially regulates different aspects of RA-induced diffe-
rentiation [35], PDGFRβ phosphorylation at Tyr 1021, a
response associated with mimicking retinoic acid syn-
drome in this model [31], was also enhanced by the RA
plus FICZ combination treatment compared to RA treat-
ment alone.AhR is involved in both promoting and inhibiting pro-
liferation. AhR has been implicated with historically well-
known pro-proliferative functions. For example, benzene,
an AhR agonist, is known to induce both leukemia and
multiple myeloma [36]. But AhR has also been shown to
have a role in propelling breast cancer [9] and liver can-
cer [10] cell differentiation. The present results suggest
that RA may set a context for AhR to act in an anti-
proliferation pro-differentiation capacity. Here we provide
evidence for a novel way of using an endogenous AhR
ligand to enhance RA-induced differentiation associated
with the unanticipated modulation of components of the
MAPK and Src-family kinase signaling machine/signalsome
thought to drive RA-induced differentiation (summarized
in Figure 6).
The present results suggest cooperative crosstalk be-
tween the RA and FICZ elicited pathways in driving diffe-
rentiation. How this occurs molecularly is a matter of
conjecture that will require further experimental elucida-
tion. There are numerous pathways that RA and FICZ are
able to elicit. The most studied are RAR/RXR and AhR
transcriptional regulation pathways. There are several
ways those pathways are known to crosstalk. (1) For ex-
ample, they compete for transcriptional co-activators/re-
pressors, such as SMRT protein [5,37]. However, in our
case, the amount of SMRT that co-immunoprecipitates
with AhR does not vary with different treatments (data
not shown), suggesting that this is not the mechanism in-
volved in this case. (2) RAR and AhR can also use the
same coactivators, specifically SRC-1, steroid coactivator-1
[38,39]. (3) Retinoids are reported to be AhR ligands that
can drive AhR/ARNT to xenobiotic response elements
(XRE) and consequently regulate transcription [5]. (4)
RAR and AhR pathways can also crosstalk by regulating
the same transcription factor, notably the pro-proliferation
transcription factor AP-1. RAR can physically bind either
c-jun or c-fos resulting in a mutual inhibition of DNA-
binding activity for both RAR and AP-1 [40]. AhR is also
reported to inhibit AP-1 DNA binding activity [41]. (5)
RAR and AhR regulation of transcription can depend on
common transcription factors such as the COUP orphan
receptors which are regulators of both AhR [42] and of
RAR directed transcriptional activity [43]. There are thus
a variety of ways that RA and AhR governed pathways can
converge at the level of transcription.
While crosstalk at the level of transcriptional regula-
tion is arguably the most prominently studied, non-
nuclear/cytoplasmic interactions at the level of signaling
are also indicated. RA itself can regulate MAPK related
signaling molecules such as PKC [44,45] or c-RAF [46]
as a lipid interacting molecule with a hydrophobic
pocket [47,48]. AhR can also regulate pathways incorp-
orating MAPK signaling molecules [1,49]. AhR has been
found complexed with Src, a well-known MAPK signaling
BLAST    RA+FICZ     NEUTROPHIL 
    Upregulation of: 
  1. Signaling events: 
• pRAF  pMEK  pERK 
• c-Cbl, VAV1 
• SFK: total Fgr, total Lyn,  
p Y416 pan SFK,pY507 Lyn
• pY458 p85 PI3K
2. Phenotypic markers: 
• CD11b 
• Respiratory burst activity (p47phox expression) 
• G0/G1 arrest 
Figure 6 Summary figure.
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a downstream effector for both RA and AhR, consistent
with the possibility that RA and AhR integrate their cyto-
plasmic signaling through the MAPK axis [1,17]. AhR is
also known to have a ubiquitin E3 ligase activity that can
affect expression levels of other molecules, notably ER
which we have reported can act as a membrane receptor –
in addition to its historical nuclear function as a ligand acti-
vated transcription factor - that originates MAPK signaling
relevant to RA-induced differentiation [51]. There are thus
a number of possibilities for the mechanism of non-nuclear
as well as nuclear crosstalk already suggested in the litera-
ture. The present results motivate interest in deciphering
their roles in RA-induced differentiation augmented by
FICZ.
RA has clinically been notably successful in inducing
remissions, albeit transient, in APL, but has not been ef-
fective in other myeloid leukemias. APL is defined by
the presence of the PML-RARα fusion protein resulting
from the t(15;17) translocation that cytogenetically char-
acterizes the disease, which is a FAB M3. There is thus
potential interest from the therapeutic point of view of
bringing RA differentiation induction therapy to non-
APL FAB M2 or 1 disease. In particular mechanistic as-
pects of how a FAB M2 derived cell that is capable of
RA-induced differentiation undergoes granulocytic dif-
ferentiation and G0 cell cycle arrest may provide insights
into how to drive differentiation in a non-APL cell. Such
is HL-60, the currently used model derived from a mye-
loblastic leukemia. Hence means of driving RA-induced
differentiation here may contribute insights of thera-
peutic relevance.
Methods
Cell culture and treatments
HL-60 human myeloblastic leukemia cells derived from
the original patient isolate, a generous gift of Dr. Robert
Gallagher, were grown in RPMI 1640 (Invitrogen, Carlsbad,CA) supplemented with 5% fetal bovine serum (Hyclone,
Logan, UT) and 1x antibiotic/antimycotic (Sigma, St.
Louis, MO) in a 5% CO2 humidified atmosphere at 37°C.
The cells were cultured in constant exponential growth as
previously described [52]. The experimental cultures were
initiated at a density of 0.1 × 106 cells/ml. Viability was
monitored by 0.2% trypan blue (Invitrogen, Carlsbad, CA)
exclusion and routinely exceeded 95%. All reagents were
purchased from Sigma (St Louis, MO) unless otherwise
stated.
For treatments, all-trans-retinoic acid (RA) (Sigma, St.
Louis, MO) was added from a 5 mM stock solution in
100% ethanol to make a final concentration of 1 μM in
culture. 6-Formylindolo(3,2-b)carbazole (FICZ) (Enzo Life
Sciences, Exeter, United Kingdom), was added from a 100
μM DMSO stock to make a final concentration of 100 nM
in culture. The concentration was chosen from an initial
dose response experiment as the lower concentration
yielding a phenotypic response when added with RA with
no toxic effects. This corresponds to a frequently used
concentration in the literature. α-naphthoflavone and β-
naphthoflavone (both from Sigma, St. Louis, MO) were
each used at a final concentration of 1 μM in culture. The
stock solutions were 1 mM in DMSO. Similar to FICZ,
there was no apparent toxicity of α-NF or β-NF at this
dose discernible by proliferation rates, cell cycle distribu-
tion, or trypan blue exclusion.
CD38, CD11b quantification
Expression of cell surface differentiation markers was
quantified by flow cytometry. 1 × 106 cells were col-
lected from cultures and centrifuged at 1000 rpm for 5
min. Cell pellets were resuspended in 200 μl, 37°C, PBS
containing 2.5 μl of allophycocyanin (APC) conjugated
antibody for CD11b or CD38 (both from BD Biosci-
ences, San Jose, CA). Following a 1 h incubation at 37°C
cell surface expression levels were analyzed with a BD
LSRII flow cytometer (BD Biosciences, San Jose, CA).
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http://www.molecular-cancer.com/content/12/1/39APC is excited at 633 nm and emission collected with a
660/20 band pass filter. Undifferentiated control cells
were used to determine the fluorescence intensity of
cells negative for the respective surface antigen. The gate
to determine percent increase of expression was set to
exclude 95% of the control population.
Respiratory burst quantification
Respiratory burst (a functional differentiation marker for
mature myelo-monocytic cells) was measured by flow cy-
tometry. 1 × 106 cells were collected and centrifuged at
1000 rpm for 5 min. Cell pellets were resuspended in 500
μl 37°C PBS containing 5 μM 5-(and-6)-chloromethyl-
2′,7′-dichlorodihydro–fluorescein diacetate acetyl ester
(H2-DCF, Molecular Probes, Eugene, OR) and 0.2 μg/ml
12-o-tetradecanoylphorbol-13-acetate (TPA, Sigma, St.
Louis, MO). H2-DCF and TPA stock solutions were made
in DMSO (Sigma, St. Louis, MO) at concentrations of 0.2
mg/ml and 5 mM, respectively. A control group incubated
in H2-DCF and DMSO only was included. Cells were
incubated for 20 min at 37°C prior to analysis by flow
cytometry. Oxidized DCF was excited by a 488 nm laser
and emission collected with a 530/30 nm band pass filter.
The shift in fluorescence intensity in response to TPA was
used to determine the percent cells with the capability to
generate inducible oxidative metabolites [36]. Gates to
determine percent positive cells were set to exclude 95%
of control cells not stimulated with TPA.
Cell cycle quantification
1 × 106 cells were collected by centrifugation and
resuspended in 200 μl of cold propidium iodide (PI) hypo-
tonic staining solution containing 50 μg/ml propidium
iodine, 1 μl/ml Triton X-100, and 1 mg/ml sodium citrate
(all from Sigma, St. Louis, MO). Cells were incubated at
room temperature for 1h and their nuclei analyzed by flow
cytometry (BD LSRII) using 488-nm excitation and emis-
sion collected with a 575/26 band-pass filter. Doublets
were identified by a PI signal width versus area plot and
excluded from the analysis [36].
Protein detection by Western blot
2 × 107 cells were lysed using 200 μL lysis buffer (Pierce,
Rockford, IL) and lysates were cleared by centrifugation at
13,000 rpm for 30 min at 4°C. Equal amounts of protein
lysates (25 μg) were resolved by SDS-PAGE gel electropho-
resis, transferred to PVDF membranes and probed with
antibodies. AhR (H211), c-Cbl (C-15) and p Y1021 PDGFRβ
antibodies were from Santa Cruz Biotechnology (Santa
Cruz, CA). IRF-1 and CD38 antibodies were from BD
Biosciences (San Jose, CA). Antibodies to detect phospho-
p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (D13.14.4E),
p44/42 MAPK (ERK1/2) (137F5), pS221 MEK1/2, MEK1/2,
p-Y416 pan-SFK, Lyn, pY507 Lyn, p-PI3K p85(Y458)/p55(Y199), Fgr, VAV1, p47phox, pS289/296/301 c-RAF (TD
cRAF), RARα, and GAPDH, horseradish peroxidase anti-
mouse and horseradish peroxidase anti-rabbit were from
Cell Signaling (Danvers, MA, USA). pS621 c-RAF antibody
was from Invitrogen (Carlsbad, CA). Cyp1A2 antibody was
from Abcam (Cambridge, MA). ECL (GE Healthcare, Pitts-
burgh, PA) was used for detection.
Statistical analysis
Statistical analyses were performed using GraphPad
(GraphPad software, San Diego, CA). Means of treatment
groups of interest were compared using the Paired-Samples
T Test. The data represents the means of three repeats ±
S.E.M. A p-value of < 0.05 was considered significant.
Additional file
Additional file 1: Figure S1. CD11b Mean Fluorescence Index (MFI)
Shift. The flow cytometry raw data and mean fluorescence index for
CD11b of a representative experiment (48 h and 72 h) are presented.
CD11b expression was assessed by flow cytometry with APC-conjugated
antibody. HL-60 cells were untreated (C, control) or treated with FICZ, RA,
or RA plus FICZ. Cells treated with FICZ alone showed no CD11b
expression – like untreated controls.
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